1. Scrip
  2. >>Business

After Lixi: What Zealand Is Doing Next

 
• By Sten Stovall

Zealand CEO Britt Meelby Jensen says the Danish developer of novel peptides for treating gastrointestinal and metabolic diseases is successfully raising its global profile via a growing proprietary pipeline.

Magnify
Zealand's CEO Seeks To Focus Attention On Its Proprietary Pipeline • Source: Shutterstock

Denmark-basedZealand Pharma AS says its profile among international investors has benefited hugely since its shares were listed on the US Nasdaq last August, giving it exposure to highlight a promising late-stage proprietary pipeline and ongoing collaborations with Sanofi and Boehringer Ingelheim GMBH.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business

GSK Chief Optimistic About BD Despite Volatile Environment

 
• By Kevin Grogan

Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.

Pfizer CEO Bourla ‘Cautiously Optimistic’ About Tariffs, Pricing Policies

 
• By Mandy Jackson

Bourla said the pharma industry may be able to negotiate productive solutions to Trump tariff and drug pricing concerns. He asserted anti-science views are not shared by all in the administration.

Abeona Sets $3.1m Price For Rare Skin Disorder Gene Therapy

 
• By Joseph Haas

Abeona plans to offer an outcomes-based payment model for Zevaskyn, which likely will see complementary use with Krystal’s Vyjuvek in recessive dystrophic epidermolysis bullosa patients.